clinical trial · NCT07053345
A Study of Esketamine Nasal Spray in Korean Participants With Treatment-resistant Depression
Janssen Korea, Ltd., Korea·phase4·recruiting·n = 47
Depressive Disorder, Treatment-ResistantEsketamine 56 mgEsketamine 84 mg
brief summary
The purpose of this study is to evaluate how well esketamine nasal spray works in improving depressive symptoms in participants with treatment resistant depression (TRD). This will be assessed by the change from baseline in the Hamilton depression rating scale (HAM-D; 17-item) total score from Day 1 (baseline) to the end of the 4-week treatment phase (Day 28).
started
Jun 9, 2025
primary completion
Jun 25, 2027
completion
Jun 25, 2027
last updated
Jun 5, 2026
official title
An Interventional, Open-label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of Esketamine Nasal Spray in Korean Participants With Treatment-Resistant Depression(TRD)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol